Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 15/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.59 |
| ▸ | PPARA | Q07869 | 10/20 | 0.58 |
| ▸ | PPARG | P37231 | 7/20 | 0.58 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848494 | 0.90 | PPARD (0.70) | PPARDFFAR1PPARAPPARG | |
| SCHEMBL5847993 | 0.85 | PPARD (0.57) | PPARDFFAR1PPARAPPARGCHRM5 | |
| SCHEMBL5475700 | 0.83 | PPARD (0.78) | PPARDFFAR1PPARAPPARGCHRM5 | |
| SCHEMBL5848492 | 0.82 | PPARD (0.62) | PPARDFFAR1PPARAPPARGCHRM5 | |
| SCHEMBL5480585 | 0.82 | PPARD (0.79) | PPARDFFAR1PPARAPPARGCHRM5 | |
| SCHEMBL5848692 | 0.81 | PPARD (0.64) | PPARDFFAR1PPARAPPARGCHRM5 | |
| SCHEMBL5848821 | 0.81 | PPARD (0.58) | PPARDFFAR1PPARAPPARGCHRM5 | |
| SCHEMBL14573031 | 0.79 | PPARD (0.63) | PPARDFFAR1PPARAPPARG | |
| SCHEMBL7103151 | 0.78 | PTPN1 (0.53) | PPARDFFAR1PPARAPPARG | |
| SCHEMBL5129094 | 0.77 | PPARD (0.77) | PPARDFFAR1PPARAPPARGCHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091225-B2 | Substituted oxazoles and thiazoles as hPPAR alpha agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | claimed |
| US-20040147571-A1 | Substituted oxazoles and thiazoles as hppar alpha agonists | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | claimed |
| US-7091225-B2 | Substituted oxazoles and thiazoles as hPPAR alpha agonists | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20040147571-A1 | Substituted oxazoles and thiazoles as hppar alpha agonists | SMITHKLINE BEECHAM CORPORATION | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147571-A1 | Substituted oxazoles and thiazoles as hppar alpha agonists | GLP1R, GCGR, CCKAR | PPARD 265/4885FFAR1 37/4885PPARA 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.